Revenue
353 million USD
2026 Q3 · USD
Exact inputs and evidence
- Revenue: 353171000 USD Source
Fundies. English
BridgeBio Pharma, Inc.
EDGARAnnual consolidated revenue for 2025: about USD 502.1M, using the latest reported figures. The previous period, 2024, was about USD 221.9M.
Latest quarter
Operating margin
-3.3%
2026 Q3 · %
Operating cash flow
-44.2 million USD
2026 Q3 · USD
Free cash flow
-44.5 million USD
2026 Q3 · USD
- Cash and cash equivalents
- 1.53 billion USD Source
Exact value
1533363000 USD
- Long-term debt including current maturities
- 2.63 billion USD Source
Exact value
2630054000 USD
- Shares outstanding
- 196 million shares Source
Exact value
196004842 shares
Reported share-count change
1.75% · 3.37 million shares
Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.
Trailing twelve months
The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.
Revenue
946 million USD
2025-10-01 – 2026-09-30
Exact inputs and evidence
Operating cash flow
-369 million USD
2025-10-01 – 2026-09-30
Exact inputs and evidence
- Operating cash flow: -445910000 USD · 2025-01-01 – 2025-12-31 Source
- Operating cash flow: -389490000 USD · 2025-01-01 – 2025-09-30 Source
- Operating cash flow: -197279000 USD · 2026-01-01 – 2026-03-31 Source
- Operating cash flow: -268380000 USD · 2026-01-01 – 2026-06-30 Source
- Operating cash flow: -197279000 USD · 2026-01-01 – 2026-03-31 Source
- Operating cash flow: -312550000 USD · 2026-01-01 – 2026-09-30 Source
- Operating cash flow: -268380000 USD · 2026-01-01 – 2026-06-30 Source
Capital expenditure
835 thousand USD
2025-10-01 – 2026-09-30
Exact inputs and evidence
- Capital expenditure: 1097000 USD · 2025-01-01 – 2025-12-31 Source
- Capital expenditure: 1064000 USD · 2025-01-01 – 2025-09-30 Source
- Capital expenditure: 69000 USD · 2026-01-01 – 2026-03-31 Source
- Capital expenditure: 512000 USD · 2026-01-01 – 2026-06-30 Source
- Capital expenditure: 69000 USD · 2026-01-01 – 2026-03-31 Source
- Capital expenditure: 802000 USD · 2026-01-01 – 2026-09-30 Source
- Capital expenditure: 512000 USD · 2026-01-01 – 2026-06-30 Source
Free cash flow
-370 million USD
2025-10-01 – 2026-09-30
Exact inputs and evidence
- Operating cash flow: -445910000 USD · 2025-01-01 – 2025-12-31 Source
- Operating cash flow: -389490000 USD · 2025-01-01 – 2025-09-30 Source
- Operating cash flow: -197279000 USD · 2026-01-01 – 2026-03-31 Source
- Operating cash flow: -268380000 USD · 2026-01-01 – 2026-06-30 Source
- Operating cash flow: -197279000 USD · 2026-01-01 – 2026-03-31 Source
- Operating cash flow: -312550000 USD · 2026-01-01 – 2026-09-30 Source
- Operating cash flow: -268380000 USD · 2026-01-01 – 2026-06-30 Source
- Capital expenditure: 1097000 USD · 2025-01-01 – 2025-12-31 Source
- Capital expenditure: 1064000 USD · 2025-01-01 – 2025-09-30 Source
- Capital expenditure: 69000 USD · 2026-01-01 – 2026-03-31 Source
- Capital expenditure: 512000 USD · 2026-01-01 – 2026-06-30 Source
- Capital expenditure: 69000 USD · 2026-01-01 – 2026-03-31 Source
- Capital expenditure: 802000 USD · 2026-01-01 – 2026-09-30 Source
- Capital expenditure: 512000 USD · 2026-01-01 – 2026-06-30 Source
Includes later revisions to earlier periods. Annual charts exclude incomplete years.
Latest filing recorded: 2026-10-29.
Financial data available through: 2025-12-31.
Coverage by financial measure
- Revenue: 7 of 11 periods available· newest 2025-12-31
- Operating income: 9 of 11 periods available· newest 2025-12-31
- net income: No compatible figures in this window
- Operating cash flow: 9 of 11 periods available· newest 2025-12-31
- Capital expenditure: 9 of 11 periods available· newest 2025-12-31
- Total assets: 7 of 11 periods available· newest 2025-12-31
- Total liabilities: 7 of 11 periods available· newest 2025-12-31
- Current assets: 7 of 11 periods available· newest 2025-12-31
- Current liabilities: 7 of 11 periods available· newest 2025-12-31
- Cash and cash equivalents: 7 of 11 periods available· newest 2025-12-31
- Long-term debt including current maturities: 3 of 11 periods available· newest 2025-12-31
- Shares outstanding: 7 of 11 periods available· newest 2025-12-31
Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.
What changed year over year
Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.
Revenue
+126.3%Prior period
USD 221.9 million
–
Current period
USD 502.08 million
–
Exact inputs and evidence
502076000 − 221902000 = 280174000 USD
221902000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source502076000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current sourceShare or cite
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
+USD 74.82 millionPrior period
−USD 520.73 million
–
Current period
−USD 445.91 million
–
Exact inputs and evidence
-445910000 − -520726000 = 74816000 USD
-520726000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source-445910000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current sourceShare or cite
The citation records this snapshot. The page link may show a newer release later.
Capital expenditure
+17.6%Prior period
USD 933,000
–
Current period
USD 1.1 million
–
Exact inputs and evidence
1097000 − 933000 = 164000 USD
933000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source1097000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current sourceShare or cite
The citation records this snapshot. The page link may show a newer release later.
Comparable inputs unavailable for: Net income.
Where revenue goes
How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.
2025 2025-01-01 – 2025-12-31
- Revenue USD 502.08 million 100% of revenue
- Cost of revenue USD 20.96 million 4.2% of revenue
- Operating expenses USD 983.18 million 196% of revenue
- Other operating costs Derived USD 21.35 million 4.3% of revenue
- Operating income −USD 523.41 million −104% of revenue
- Tax, interest and other Derived Unavailable An input is unavailable.
- Net income Unavailable An input is unavailable.
Cash
- Operating cash flow −USD 445.91 million −89% of revenue
- Capital expenditure USD 1.1 million 0.2% of revenue
- Free cash flow Derived −USD 447.01 million −89% of revenue
Share of revenue by period
- Net income
- Tax, interest and other
- Operating costs
- 2019 Not shown: operating income or net income is not reported.
- 2020 Not shown: operating income or net income is not reported.
- 2021 Not shown: operating income or net income is not reported.
- 2022 Not shown: operating income or net income is not reported.
- 2023 Not shown: operating income or net income is not reported.
- 2024 Not shown: operating income or net income is not reported.
- 2025 Not shown: operating income or net income is not reported.
Values and sources
| Period | Revenue | Operating costs | Operating income | Tax, interest and other | Net income | Free cash flow | Source |
|---|---|---|---|---|---|---|---|
| 2019 2019-01-01 – 2019-12-31 | 40560000 | 306800000 Derived | -266240000 | Unavailable | Unavailable | -256225000 Derived | Source
|
| 2020 2020-01-01 – 2020-12-31 | 8249000 | 482731000 Derived | -474482000 | Unavailable | Unavailable | -407232000 Derived | Source
|
| 2021 2021-01-01 – 2021-12-31 | 69716000 | 646348000 Derived | -576632000 | Unavailable | Unavailable | -511180000 Derived | Source
|
| 2022 2022-01-01 – 2022-12-31 | 77648000 | 589850000 Derived | -512202000 | Unavailable | Unavailable | -424315000 Derived | Source
|
| 2023 2023-01-01 – 2023-12-31 | 9303000 | 616673000 Derived | -607370000 | Unavailable | Unavailable | -529026000 Derived | Source
|
| 2024 2024-01-01 – 2024-12-31 | 221902000 | 814875000 Derived | -592973000 | Unavailable | Unavailable | -521659000 Derived | Source
|
| 2025 2025-01-01 – 2025-12-31 | 502076000 | 1025487000 Derived | -523411000 | Unavailable | Unavailable | -447007000 Derived | Source
|
Amounts are exact, in USD.
Growth
Sales over time and how quickly they are changing.
Revenue
Revenue reported for each complete financial period.
USD 502.1M 2025
Values and sources
| Period | Series | Value(USD) | Source evidence |
|---|---|---|---|
| 2019 | Revenue | 40560000 |
|
| 2020 | Revenue | 8249000 |
|
| 2021 | Revenue | 69716000 |
|
| 2022 | Revenue | 77648000 |
|
| 2023 | Revenue | 9303000 |
|
| 2024 | Revenue | 221902000 |
|
| 2025 | Revenue | 502076000 |
|
Revenue growth
Change in revenue from the same financial period one year earlier.
126.3% 2025
Values and sources
| Period | Series | Value | Source evidence |
|---|---|---|---|
| 2019 | Year over year | No prior comparable period |
|
| 2020 | Year over year | -79.7% |
|
| 2021 | Year over year | 745.1% |
|
| 2022 | Year over year | 11.4% |
|
| 2023 | Year over year | -88% |
|
| 2024 | Year over year | 2,285.3% |
|
| 2025 | Year over year | 126.3% |
|
Profit and cash
How much revenue becomes profit, and how much cash operations generate.
Profit margins
Operating income, net income and free cash flow as a share of revenue.
Operating margin -104.2% 2025
Free cash flow margin -89% 2025
- Operating margin
- Net margin
- Free cash flow margin
Values and sources
| Period | Series | Value | Source evidence |
|---|---|---|---|
| 2019 | Operating margin | -656.4% |
|
| 2020 | Operating margin | -5,752% |
|
| 2021 | Operating margin | -827.1% |
|
| 2022 | Operating margin | -659.6% |
|
| 2023 | Operating margin | -6,528.8% |
|
| 2024 | Operating margin | -267.2% |
|
| 2025 | Operating margin | -104.2% |
|
| 2019-12-31 | Net margin | Not reported |
|
| 2020-12-31 | Net margin | Not reported |
|
| 2021-12-31 | Net margin | Not reported |
|
| 2022-12-31 | Net margin | Not reported |
|
| 2023-12-31 | Net margin | Not reported |
|
| 2024-12-31 | Net margin | Not reported |
|
| 2025-12-31 | Net margin | Not reported |
|
| 2019 | Free cash flow margin | -631.7% |
|
| 2020 | Free cash flow margin | -4,936.7% |
|
| 2021 | Free cash flow margin | -733.2% |
|
| 2022 | Free cash flow margin | -546.5% |
|
| 2023 | Free cash flow margin | -5,686.6% |
|
| 2024 | Free cash flow margin | -235.1% |
|
| 2025 | Free cash flow margin | -89% |
|
Operating cash flow
Cash generated by the company’s normal business operations.
USD -445.9M 2025
Values and sources
| Period | Series | Value(USD) | Source evidence |
|---|---|---|---|
| 2019 | Operating cash flow | -253587000 |
|
| 2020 | Operating cash flow | -399714000 |
|
| 2021 | Operating cash flow | -497934000 |
|
| 2022 | Operating cash flow | -419494000 |
|
| 2023 | Operating cash flow | -527720000 |
|
| 2024 | Operating cash flow | -520726000 |
|
| 2025 | Operating cash flow | -445910000 |
|
Free cash flow
Operating cash flow minus capital expenditure for the same period and unit.
USD -447M 2025
Values and sources
| Period | Series | Value(USD) | Source evidence |
|---|---|---|---|
| 2019 | Free cash flow | -256225000 |
|
| 2020 | Free cash flow | -407232000 |
|
| 2021 | Free cash flow | -511180000 |
|
| 2022 | Free cash flow | -424315000 |
|
| 2023 | Free cash flow | -529026000 |
|
| 2024 | Free cash flow | -521659000 |
|
| 2025 | Free cash flow | -447007000 |
|
Balance sheet
Liabilities and short-term ability to meet obligations at each period end.
Liabilities to assets
Total liabilities as a share of total assets.
321.9% 2025
Values and sources
| Period | Series | Value | Source evidence |
|---|---|---|---|
| 2019 | Liabilities / assets | 24.6% |
|
| 2020 | Liabilities / assets | 84.7% |
|
| 2021 | Liabilities / assets | 185.5% |
|
| 2022 | Liabilities / assets | 299.8% |
|
| 2023 | Liabilities / assets | 345.7% |
|
| 2024 | Liabilities / assets | 258.6% |
|
| 2025 | Liabilities / assets | 321.9% |
|
Current assets to current liabilities
Current assets divided by current liabilities.
2.77× 2025
Values and sources
| Period | Series | Value | Source evidence |
|---|---|---|---|
| 2019 | Current assets / current liabilities | 9.42× |
|
| 2020 | Current assets / current liabilities | 6.72× |
|
| 2021 | Current assets / current liabilities | 6.58× |
|
| 2022 | Current assets / current liabilities | 4.52× |
|
| 2023 | Current assets / current liabilities | 3.32× |
|
| 2024 | Current assets / current liabilities | 4.67× |
|
| 2025 | Current assets / current liabilities | 2.77× |
|
Cash generation
Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.
| Period | Net income | Operating cash flow | Capital expenditure | Free cash flow |
|---|---|---|---|---|
| 2017 2017-01-01 – 2017-12-31 | Unavailable Not reported for this period. | −USD 40.49 million Exact valueExact value: -40488000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | USD 464,000 Exact valueExact value: 464000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 40.95 million Calculation and evidence-40488000 − 464000 USD Exact free cash flow: -40952000 USD
Share or citeThe citation records this snapshot. The page link may show a newer release later. |
| 2018 2018-01-01 – 2018-12-31 | Unavailable Not reported for this period. | −USD 136.64 million Exact valueExact value: -136643000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | USD 2.18 million Exact valueExact value: 2178000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 138.82 million Calculation and evidence-136643000 − 2178000 USD Exact free cash flow: -138821000 USD
Share or citeThe citation records this snapshot. The page link may show a newer release later. |
| 2019 2019-01-01 – 2019-12-31 | Unavailable Not reported for this period. | −USD 253.59 million Exact valueExact value: -253587000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | USD 2.64 million Exact valueExact value: 2638000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 256.23 million Calculation and evidence-253587000 − 2638000 USD Exact free cash flow: -256225000 USD
Share or citeThe citation records this snapshot. The page link may show a newer release later. |
| 2020 2020-01-01 – 2020-12-31 | Unavailable Not reported for this period. | −USD 399.71 million Exact valueExact value: -399714000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | USD 7.52 million Exact valueExact value: 7518000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 407.23 million Calculation and evidence-399714000 − 7518000 USD Exact free cash flow: -407232000 USD
Share or citeThe citation records this snapshot. The page link may show a newer release later. |
| 2021 2021-01-01 – 2021-12-31 | Unavailable Not reported for this period. | −USD 497.93 million Exact valueExact value: -497934000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | USD 13.25 million Exact valueExact value: 13246000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 511.18 million Calculation and evidence-497934000 − 13246000 USD Exact free cash flow: -511180000 USD
Share or citeThe citation records this snapshot. The page link may show a newer release later. |
| 2022 2022-01-01 – 2022-12-31 | Unavailable Not reported for this period. | −USD 419.49 million Exact valueExact value: -419494000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | USD 4.82 million Exact valueExact value: 4821000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 424.32 million Calculation and evidence-419494000 − 4821000 USD Exact free cash flow: -424315000 USD
Share or citeThe citation records this snapshot. The page link may show a newer release later. |
| 2023 2023-01-01 – 2023-12-31 | Unavailable Not reported for this period. | −USD 527.72 million Exact valueExact value: -527720000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | USD 1.31 million Exact valueExact value: 1306000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 529.03 million Calculation and evidence-527720000 − 1306000 USD Exact free cash flow: -529026000 USD
Share or citeThe citation records this snapshot. The page link may show a newer release later. |
| 2024 2024-01-01 – 2024-12-31 | Unavailable Not reported for this period. | −USD 520.73 million Exact valueExact value: -520726000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | USD 933,000 Exact valueExact value: 933000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 521.66 million Calculation and evidence-520726000 − 933000 USD Exact free cash flow: -521659000 USD
Share or citeThe citation records this snapshot. The page link may show a newer release later. |
| 2025 2025-01-01 – 2025-12-31 | Unavailable Not reported for this period. | −USD 445.91 million Exact valueExact value: -445910000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | USD 1.1 million Exact valueExact value: 1097000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 447.01 million Calculation and evidence-445910000 − 1097000 USD Exact free cash flow: -447007000 USD
Share or citeThe citation records this snapshot. The page link may show a newer release later. |
Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.
Dataset coverage and company identifiers
Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.
51 filings · 2,746 latest values · 2,745 originally reported values
Dataset published . Source filing dates and reporting periods are shown separately.
Identifiers: 0001743881, 1743881, BBIO, edgar:1743881
Also known as BridgeBio Pharma LLC, BridgeBio Pharma, Inc, BridgeBio Pharma, Inc.